Role of microRNA-30c in lipid metabolism, adipogenesis, cardiac remodeling and cancer

Current Opinion in Lipidology

Volumn 26, Issue 2, 2015, Pages 139-146

  Irani, Sara ^a,b   Hussain, M Mahmood ^b,c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Downstate Health Sciences University   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; cancer; hyperlipidemia; lipoproteins; miR 30c

Indexed keywords

MICRORNA; MICRORNA 30; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; MIRN30 MICRORNA, HUMAN;

ADIPOCYTE; ADIPOGENESIS; ATHEROSCLEROSIS; BIOGENESIS; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; DOWN REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN SECRETION; NEOPLASM; PRIORITY JOURNAL; REVIEW; UPREGULATION; ANIMAL; GENETICS; HEART VENTRICLE REMODELING; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE;

ADIPOGENESIS; ANIMALS; HUMANS; LIPID METABOLISM; MICRORNAS; NEOPLASMS; RNA INTERFERENCE; VENTRICULAR REMODELING;

EID: 84949678696     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000162     Document Type: Review

References (83)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-233.
2. Friedman RC, Farh KKH, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105.
3. De Guire V, Caron M, Scott N, et al. Designing small multiple-Target artificial RNAs. Nucleic Acids Res 2010; 38:e140.
4. Sylvestre Y, De Guire V, Querido E, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 2007; 282:2135-2143.
5. Cuellar TL, McManus MT. MicroRNAs and endocrine biology. J Endocrinol 2005; 187:327-332.
6. Bruneau BG. Developmental biology: tiny brakes for a growing heart. Nature 2005; 436:181-182.
7. Fernandez-Hernando C, Ramirez CM, Goedeke L, et al. MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 2013; 33:178-185.
8. Fernandez-Hernando C, Sua rez Y, Rayner KJ, et al. MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011; 22:86-92.
9. Moore KJ, Rayner KJ, Sua rez Y, et al. microRNAs and cholesterol metabolism. Trends Endocrinol Metab 2010; 21:699-706.
10. Novak J, Bienertova-Vas?ku J, Ka ra T, et al. MicroRNAs involved in the lipid metabolism and their possible implications for atherosclerosis development and treatment. Mediators Inflamm 2014; 2014:275867.
11. Soh J, Iqbal J, Queiroz J, et al. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013; 19:892-900.
12. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136:642-655.
13. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009; 10:126-139.
14. Lee Y, Jeon K, Lee J-T, et al. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002; 21:4663-4670.
15. Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export of premicroRNAs and short hairpin RNAs. Genes Dev 2003; 17:3011-3016.
16. Lund E, Gu ttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004; 303:95-98.
17. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-Dependent dsRNA-binding protein that mediates nuclear export of premiRNAs. RNA 2004; 10:185-191.
18. Zeng Y, Cullen BR. Structural requirements for premicroRNA binding and nuclear export by Exportin 5. Nucleic Acids Res 2004; 32:4776-4785.
19. Hutvagner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001; 293:834-838.
20. Ketting RF, Fischer SE, Bernstein E, et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 2001; 15:2654-2659.
21. Zhang H, Kolb FA, Brondani V, et al. Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J 2002; 21:5875-5885.
22. Zhang H, Kolb FA, Jaskiewicz L, et al. Single processing center models for human Dicer and bacterial RNase III. Cell 2004; 118:57-68.
23. Cheloufi S, Dos Santos CO, Chong MMW, et al. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 2010; 465:584-589.
24. Yang J-S, Maurin T, Robine N, et al. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S A 2010; 107:15163-15168.
25. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
26. Grimson A, Farh KK-H, Johnston WK, et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27:91-105.
27. Wee LM, Flores-Jasso CF, Salomon WE, et al. Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties. Cell 2012; 151:1055-1067.
28. Soh J, Hussain MM. Supplementary site interactions are critical for the regulation of microsomal triglyceride transfer protein by microRNA-30c. Nutr Metab (Lond) 2013; 10:56.
29. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science 2001; 294:853-858.
30. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12:735-739.
31. Alexiou P, Vergoulis T, Gleditzsch M, et al. miRGen 2.0: a database of microRNA genomic information and regulation. Nucleic Acids Res 2010; 38:D137-D141.
32. Karbiener M, Neuhold C, Opriessnig P, et al. MicroRNA-30c promotes human adipocyte differentiation and co-represses PAI-1 and ALK2. RNA Biol 2011; 8:850-860.
33. Bockhorn J, Dalton R, Nwachukwu C, et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013; 4:1393.
34. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics: 2013 update: a report from the American Heart Association. Circulation 2013; 127:e6-E245.
35. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003; 44:22-32.
36. Hussain MM, Rava P, Walsh M, et al. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond) 2012; 9:14.
37. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
38. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
39. Hussain MM, Bakillah A. New approaches to target microsomal triglyceride transfer protein. Curr Opin Lipidol 2008; 19:572-578.
40. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356:148-156.
41. Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol 2013; 24:246-250.
42. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-Arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
43. Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5:497-505.
44. Burnett JR, Watts GF. MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?. Expert Opin Ther Targets 2007; 11:181-189.
45. Joy TR, Hegele RA. Microsomal triglyceride transfer protein inhibition-friend or foe?. Nat Clin Pract Cardiovasc Med 2008; 5:506-508.
46. Josekutty J, Iqbal J, Iwawaki T, et al. Microsomal triglyceride transfer protein inhibition induces endoplasmic reticulum stress and increases gene transcription via Ire1(/cJun to enhance plasma ALT/AST. J Biol Chem 2013; 288:14372-14383.
47. Rayner KJ, Sua rez Y, Da valos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328:1570-1573.
48. Moore KJ, Rayner KJ, Sua rez Y, et al. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr 2011; 31:49-63.
49. Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566-1569.
50. Marquart TJ, Allen RM, Ory DS, et al. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 2010; 107:12228-12232.
51. Lau DCW, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288:H2031-H2041.
52. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11:327-332.
53. Mudhasani R, Imbalzano AN, Jones SN. An essential role for dicer in adipocyte differentiation. J Cell Biochem 2010; 110:812-816.
54. Mudhasani R, Puri V, Hoover K, et al. Dicer is required for the formation of white but not brown adipose tissue. J Cell Physiol 2011; 226:1399-1406.
55. Zaragosi L-E, Wdziekonski B, Brigand K Le, et al. Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol 2011; 12:R64.
56. Sun T, Fu M, Bookout AL, et al. MicroRNA let-7 regulates 3T3-L1 adipogenesis. Mol Endocrinol 2009; 23:925-931.
57. Zhu Y, Zhang X, Ding X, et al. miR-27 inhibits adipocyte differentiation via suppressing CREB expression. Acta Biochim Biophys Sin (Shanghai) 2014; 46:590-596.
58. Kim SY, Kim AY, Lee HW, et al. miR-27a is a negative regulatkaror of adipocyte differentiation via suppressing PPARgamma expression. Biochem Biophys Res Commun 2010; 392:323-328.
59. Gerin I, Bommer GT, McCoin CS, et al. Roles for miRNA-378/378-in adipocyte gene expression and lipogenesis. Am J Physiol Endocrinol Metab 2010; 299:E198-206.
60. Esau C, Kang X, Peralta E, et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004; 279:52361-52365.
61. Karbiener M, Fischer C, Nowitsch S, et al. microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. Biochem Biophys Res Commun 2009; 390:247-251.
62. Kim YJ, Hwang SJ, Bae YC, et al. MiR-21 regulates adipogenic differentiation through the modulation of TGF-beta signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells 2009; 27:3093-3102.
63. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104:170-178.
64. Gambacciani C, Kusmic C, Chiavacci E, et al. miR-29a and miR-30c negatively regulate DNMT 3a in cardiac ischemic tissues: implications for cardiac remodelling. microRNA Diagnostics Ther 2013; 1:35-45.
65. Bockhorn J, Yee K, Chang Y, et al. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat 2013; 137:373-382.
66. Tanic M, Yanowsky K, Rodriguez-Antona C, et al. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One 2012; 7:e38847.
67. Zhou H, Xu X, Xun Q, et al. microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-Associated gene-1. Oncol Rep 2012; 27:807-812.
68. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010; 122:2727-2735.
69. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012; 92:635-688.
70. Hall-Glenn F, De Young RA, Huang B-L, et al. CCN2/connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis. PLoS One 2012; 7:e30562.
71. Jentzsch C, Leierseder S, Loyer X, et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol 2012; 52:13-20.
72. Wijnen WJ, van der Made I, van den Oever S, et al. Cardiomyocyte-specific miRNA-30c over-Expression causes dilated cardiomyopathy. PLoS One 2014; 9:e96290.
73. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006; 66:7390-7394.
74. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866.
75. Volinia S, Calin Ga, Liu C-G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103:2257-2261.
76. Rodriguez-Gonza lez FG, Sieuwerts AM, Smid M, et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011; 127:43-51.
77. Kong X, Xu X, Yan Y, et al. Estrogen regulates the tumour suppressor MiRNA-30c and its target gene, MTA-1, in endometrial cancer. PLoS One 2014; 9:e90810.
78. Ren Q, Liang J, Wei J, et al. Epithelial and stromal expression of miRNAs during prostate cancer progression. Am J Transl Res 2014; 6:329-339.
79. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67:6130-6135.
80. Ozen M, Creighton CJ,Ozdemir M, et al.Widespread deregulation of microRNA expression in human prostate cancer Oncogene 2008 27 1788-1793.
81. Ling X, Han Z, Xia D, et al. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep 2014; 41:2779-2788.
82. Lee H, Park CS, Deftereos G, et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol 2012; 10:174.
83. Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009; 4:e5311.